Previous close | 1.2500 |
Open | 1.2400 |
Bid | 1.2200 x 1100 |
Ask | 1.2300 x 2900 |
Day's range | 1.2000 - 1.2500 |
52-week range | 1.2000 - 5.3900 |
Volume | |
Avg. volume | 746,768 |
Market cap | 107.694M |
Beta (5Y monthly) | 1.18 |
PE ratio (TTM) | 0.69 |
EPS (TTM) | 1.7700 |
Earnings date | 15 May 2023 - 19 May 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 7.33 |
- Continued Execution and Progress Towards Commercial Approval of Dordaviprone (ONC201) with Global Launch of Phase 3 ACTION Study – – Confirmed Response in Non-H3 K27M Recurrent Glioblastoma Patient During ONC206 Dose Escalation – – Strong Balance Sheet with $266 Million in Cash at Year-End and No Debt – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C., March 02, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaning
DURHAM, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman, Chief Executive Officer, will participate in a Targeted Oncology Panel at the Cowen and Company 43rd Annual Health Care Conference on Tuesday, March 7, 2023 at 2:10 p.m. ET. An audio webcast of the panel discussion will be available on the Inve
DURHAM, N.C., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Thursday, March 2, 2023 at 8:30 a.m. ET to report financial results for the fourth quarter and full-year ended December 31, 2022, and to provide a business overview. To access the live conference call,